Back to List View Graph View

Bromodomain-containing protein 4 (BRD4)

BRD4 (bromodomain-containing protein 4) is a member of the BET (bromodomain and extra-terminal domain) family of epigenetic reader proteins.

Where the papers sit

21 papers from the last 6 months study Bromodomain-containing protein 4 (BRD4) directly · updated from PubMed 15 Nov 2026

Study type 0 clinical trials · 2 human data · 15 preclinical · 4 unclassified

Themes one subject · 1 paradigm shift

Those 21 are all about one subject.

  • BRD4 Drug Development

    BRD4 drug development is expanding from small-molecule inhibition toward PROTAC and nano-PROTAC degradation, including strategies that overcome CRBN or VHL deficiency and control activity in space and time. Anticancer applications dominate, spanning acute myeloid and megakaryoblastic leukemia, pancreatic, triple-negative breast, and other tumors. Combination approaches pair BRD4 targeting with PARP or HDAC inhibition, radiotherapy, oncolytic viruses, or PD-L1-directed immunotherapy, with c-JUN/CCL2 and PIM1 emerging as mechanistic vulnerabilities. Non-oncology work extends BRD4 modulation to corneal injury and idiopathic pulmonary fibrosis, but clinical translation remains open.

    21 papers

PARADIGM SHIFT

BRD4 degradation need not depend on conventional CRBN- or VHL-recruiting PROTACs

The GID4-recruiting BRD4 degrader study and the RIPK1-mediated RIMTAC study assumed the usual PROTAC architecture was constrained by reliance on CRBN or direct VHL recruitment; instead, the GID4 ligand a11 degraded BRD4 in CRBN- and VHL-deficient models, while RIMTAC recruited VHL indirectly through a RIPK1–VHL complex to degrade BRD4. Together, they replace dependence on the conventional recruitment routes with viable alternative mechanisms that can overcome E3-ligase deficiencies and broaden the design space for BRD4 degraders 42402035Jul 42417401Jul.

Papers

The 21 papers from the last 6 months that study Bromodomain-containing protein 4 (BRD4) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

BRD4 Drug Development (21)
  1. Design and Biological Evaluation of a Potent Dual PARP and BRD4 Inhibitor for Tumor Therapy via Disrupting HRR and BRD4-cJUN-CCL2 Axis. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018612
  2. Development of a photocaged CLIPTAC for spatiotemporal control of protein degradation. Bioorganic chemistry · 25 Oct 2026 PMID 42927673
  3. Discovery of a novel BRD4 inhibitor for the treatment of acute myeloid leukemia. Bioorganic chemistry · 10 Oct 2026 PMID 42858492
  4. In Situ Bioorthogonal Synthesis of PROTACs via Dual-Responsive Cleavage for Synergistic Photo-Immunotherapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 27 Sept 2026 PMID 42801629
  5. BRD4 inhibition mitigates acute and chronic corneal injury following topical nitrogen mustard exposure. Molecular therapy : the journal of the American Society of Gene Therapy · 3 Sept 2026 PMID 42687381
  6. Development of Oncolytic Virus-Proteolysis-Targeting Chimera Conjugates for Tumor Immunotherapy. ACS nano · 18 Aug 2026 PMID 42611240
  7. Sequential Disruption of Tumor Camouflage and Metabolic Coercion by Cascade-Acting Nano-Proteolysis Targeting Chimera Engines to Reprogram the Immune Ecosystem. ACS nano · 11 Aug 2026 PMID 42579417
  8. An antibody-PROTAC conjugate targets BRD4/c-Myc/PD-L1 to enhance immunotherapy efficacy in triple-negative breast cancer. Cell reports. Medicine · 29 Jul 2026 PMID 42526440
  9. PROTAC-based nanoassemblies targeting BRD4 for potentiate FLASH radiosensitization therapy. Materials today. Bio · 12 Jul 2026 PMID 42436803
  10. RIMTAC: A Novel Degrader Design Platform by Indirect VHL-Recruitment via RIPK1. Journal of medicinal chemistry · 8 Jul 2026 PMID 42417401
  11. GID4-Recruiting PROTACs for BRD4 Degradation Overcome Resistance Driven by CRBN and VHL Deficiency. Journal of medicinal chemistry · 5 Jul 2026 PMID 42402035
  12. Identification of 3-arylquinoxalin-2(1H)-one derivatives targeting BRD4 BD1 as efficient anticancer agents. European journal of medicinal chemistry · 3 Jul 2026 PMID 42398403
  13. HDAC inhibition sensitizes pancreatic tumors to DNA damage by global redistribution of the transcriptional machinery. Proceedings of the National Academy of Sciences of the United States of America · 25 Jun 2026 PMID 42348617
  14. Inhalable Polymeric PROTAC Nanococktail for Targeted Protein Degradation in Idiopathic Pulmonary Fibrosis. Journal of the American Chemical Society · 24 Jun 2026 PMID 42341263
  15. BRD4 regulation of PIM1 identifies a novel therapeutic vulnerability in acute megakaryoblastic leukemia. Cancer cell international · 18 Jun 2026 PMID 42310709
  16. PyMolGen: Database-Driven Molecular Generation of Drug-Like Compounds. Journal of chemical information and modeling · 16 Jun 2026 PMID 42298369
  17. Design, synthesis and biological evaluation of novel CDK8/BRD4 dual inhibitors. Bioorganic & medicinal chemistry letters · 12 Jun 2026 PMID 42285310
  18. Multicomponent Stapling of Glucagon-Like Peptide-1 Enables Receptor-Guided PROTAC Delivery. Angewandte Chemie (International ed. in English) · 12 Jun 2026 PMID 42283322
  19. Targeting BRD2 and BRD4 inhibit the growth of KSHV-infected immortalized endothelial cells through suppression of LANA translation. PLoS pathogens · 1 Jun 2026 PMID 42224297
  20. Stress granule assembly represents a therapeutic vulnerability in super-enhancer-driven circMLB-mediated glioblastoma temozolomide resistance. Cancer letters · 21 May 2026 PMID 42167397
  21. Design, synthesis, and biological evaluation of 2-morpholino-4H-chromen-4-one derivatives as a potent dual PI3K/BRD4 inhibitors. European journal of medicinal chemistry · 21 May 2026 PMID 42166816

By study type

Human data, design not indexed (2)
  1. Development of a photocaged CLIPTAC for spatiotemporal control of protein degradation. Bioorganic chemistry · 25 Oct 2026 PMID 42927673
  2. Multicomponent Stapling of Glucagon-Like Peptide-1 Enables Receptor-Guided PROTAC Delivery. Angewandte Chemie (International ed. in English) · 12 Jun 2026 PMID 42283322
Preclinical: animal, cell and lab studies (15)
  1. Design and Biological Evaluation of a Potent Dual PARP and BRD4 Inhibitor for Tumor Therapy via Disrupting HRR and BRD4-cJUN-CCL2 Axis. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018612
  2. Discovery of a novel BRD4 inhibitor for the treatment of acute myeloid leukemia. Bioorganic chemistry · 10 Oct 2026 PMID 42858492
  3. BRD4 inhibition mitigates acute and chronic corneal injury following topical nitrogen mustard exposure. Molecular therapy : the journal of the American Society of Gene Therapy · 3 Sept 2026 PMID 42687381
  4. Development of Oncolytic Virus-Proteolysis-Targeting Chimera Conjugates for Tumor Immunotherapy. ACS nano · 18 Aug 2026 PMID 42611240
  5. Sequential Disruption of Tumor Camouflage and Metabolic Coercion by Cascade-Acting Nano-Proteolysis Targeting Chimera Engines to Reprogram the Immune Ecosystem. ACS nano · 11 Aug 2026 PMID 42579417
  6. An antibody-PROTAC conjugate targets BRD4/c-Myc/PD-L1 to enhance immunotherapy efficacy in triple-negative breast cancer. Cell reports. Medicine · 29 Jul 2026 PMID 42526440
  7. GID4-Recruiting PROTACs for BRD4 Degradation Overcome Resistance Driven by CRBN and VHL Deficiency. Journal of medicinal chemistry · 5 Jul 2026 PMID 42402035
  8. Identification of 3-arylquinoxalin-2(1H)-one derivatives targeting BRD4 BD1 as efficient anticancer agents. European journal of medicinal chemistry · 3 Jul 2026 PMID 42398403
  9. HDAC inhibition sensitizes pancreatic tumors to DNA damage by global redistribution of the transcriptional machinery. Proceedings of the National Academy of Sciences of the United States of America · 25 Jun 2026 PMID 42348617
  10. Inhalable Polymeric PROTAC Nanococktail for Targeted Protein Degradation in Idiopathic Pulmonary Fibrosis. Journal of the American Chemical Society · 24 Jun 2026 PMID 42341263
  11. PyMolGen: Database-Driven Molecular Generation of Drug-Like Compounds. Journal of chemical information and modeling · 16 Jun 2026 PMID 42298369
  12. Design, synthesis and biological evaluation of novel CDK8/BRD4 dual inhibitors. Bioorganic & medicinal chemistry letters · 12 Jun 2026 PMID 42285310
  13. Targeting BRD2 and BRD4 inhibit the growth of KSHV-infected immortalized endothelial cells through suppression of LANA translation. PLoS pathogens · 1 Jun 2026 PMID 42224297
  14. Stress granule assembly represents a therapeutic vulnerability in super-enhancer-driven circMLB-mediated glioblastoma temozolomide resistance. Cancer letters · 21 May 2026 PMID 42167397
  15. Design, synthesis, and biological evaluation of 2-morpholino-4H-chromen-4-one derivatives as a potent dual PI3K/BRD4 inhibitors. European journal of medicinal chemistry · 21 May 2026 PMID 42166816
Unclassified: not yet indexed with MeSH (4)
  1. In Situ Bioorthogonal Synthesis of PROTACs via Dual-Responsive Cleavage for Synergistic Photo-Immunotherapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 27 Sept 2026 PMID 42801629
  2. PROTAC-based nanoassemblies targeting BRD4 for potentiate FLASH radiosensitization therapy. Materials today. Bio · 12 Jul 2026 PMID 42436803
  3. RIMTAC: A Novel Degrader Design Platform by Indirect VHL-Recruitment via RIPK1. Journal of medicinal chemistry · 8 Jul 2026 PMID 42417401
  4. BRD4 regulation of PIM1 identifies a novel therapeutic vulnerability in acute megakaryoblastic leukemia. Cancer cell international · 18 Jun 2026 PMID 42310709